Provention bio to combine forces with sanofi to support potential u.s. launch of teplizumab for delay in onset of clinical type 1 diabetes (t1d) in at-risk individuals

Provention receives $20 million nonrefundable payment granting sanofi exclusive right of first negotiation to in-license teplizumab globally for t1d u.s. copromotion agreement leverages sanofi's in-market infrastructure and established expertise in endocrinology to expand reach, increase awareness and drive t1d screening sanofi to invest $35 million at a premium after a potential teplizumab fda approval investor conference call at 8:30am et today red bank, n.j. , oct. 6, 2022 /prnewswire/ -- provention bio, inc. (nasdaq: prvb) (the "company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the company has entered into a co-promotion agreement with sanofi u.s. for the launch of provention's lead investigational drug candidate teplizumab.
PRVB Ratings Summary
PRVB Quant Ranking